- Endometrioid Carcinoma
- Serous Adenocarcinoma
- Adenosquamous Carcinoma
Endometrial Cancer Diagnostics Market size was valued at USD 21.4 billion in 2021 and is expected to reach USD 28.4 billion by 2028, at a CAGR of 5.4% during the forecast period 2022-2028. Endometrial Cancer is the most common form of uterine cancer as the endometrium is part of the uterus. Endometrial cancer is often called uterine cancer. It is the most commonly diagnosed gynecologic cancer. Endometrial cancer forms when cells in the inner lining of the uterus (endometrium) begin to grow out of control. Unlike breast and prostate cancer where screening tests are available to the general population endometrial cancer is most commonly diagnosed at endometrial biopsy in symptomatic patients. No generally applicable screening test is available. Among all test types hysteroscopy is most commonly recommended uterine cancer diagnostic test. According to the American Cancer Society, in 2017, about 61380 new cases of uterine cancer were diagnosed and around 10,000 were dead.Â According to WHO, developed regions such as North America and Europe registers greater incidence rate for endometrial cancer due to lifestyle changes adopted by women. Women with abnormal vaginal bleeding are detected with endometrial cancer at an early stage. Endometrial cancer is the sixth most common cancer in women worldwide, according to statistics. Because of the increased prevalence of Endometrial Cancer Diagnostics Market is predicted to grow significantly. Other key factors contributing to the market's growth include rising female obesity, increased menopausal hormone therapy, changes in sedentary lifestyle, socioeconomic factors, rising consumption of unhealthy diet, rising occurrence of Polycystic Ovarian Syndrome (PCOS), and rising prevalence of breast or ovarian tumour. Another condition that contributes to the development of endometrial cancer is diabetes. Endometrial cancer is four times more likely in diabetes women than in non-diabetic women, according to the American Cancer Society. Endometrial cancer is caused by such factors in women.
Fastest Growing Market
Increase in the prevalence and incidence of endometrial cancer propels the growth of the endometrial cancer diagnostics market globally. As per the stats of American Cancer Society, in 2012, about 47,130 new cases of endometrial cases were diagnosed and 8010 women died because of it. Furthermore increase in awareness regarding uterine diseases, availability of various treatment options and early diagnostic options drives the growth of the globally. Moreover increase in healthcare expenditure, technological advancements and developments and advanced healthcare services also propels the market growth of endometrial cancer diagnostics globally. However, low accuracy rate in the results of diagnostic tests, high cost associated with the tests and treatments, adverse effects and lack of awareness about innovative technologies may hinder the growth of the globally.
The endometrial cancer diagnostics market is projected to expand at a CAGR of 5.4% during the forecast period
Abbott Laboratories, Ariad Pharmaceuticals, Merck, Becton, Dickinson, Siemens Healthcare
North America is the fastest-growing region for endometrial cancer diagnostics market